综述 Review

慢性荨麻疹非抗组胺药物治疗进展

Published at: 2017年第37卷第8期

张秋秋 1 , 雷铁池 1
1 武汉大学人民医院皮肤科,武汉 430060
通讯作者 铁池 雷 Email: lei86308656@163.com
DOI: 10.3978/j.issn.2095-6959.2017.08.032
基金:

摘要

慢性荨麻疹的一线治疗药物为第二代组胺H1受体拮抗剂,然而部分慢性难治性荨麻疹患者使用常规剂量组胺H1受体拮抗剂没有明显效果。因此,常联合非抗组胺药治疗慢性难治性荨麻疹。根据临床观察,联合治疗慢性荨麻疹的疗效明显优于单独使用组胺H1受体拮抗剂。常用的非抗组胺药物有白三烯受体拮抗剂、糖皮质激素、三环类抗抑郁药、免疫抑制剂、生物制剂等,但是非抗组胺药物的不良反应较多,建议在使用前权衡利弊,使用过程中还应注意监测不良反应的发生。


Progress of non-antihistamine therapy of chronic urticaria

Abstract

The first-line therapy for chronic urticaria is the second generation histamine H1 receptor antagonist. However, some patients with chronic refractory urticaria using regular doses of histamine H1 receptor antagonist have no obvious effect. So, we often combine histamine H1 receptor antagonist with non-antihistamine drugs to cure chronic refractory urticaria. According to clinical observation, the curative effect of combination therapy of chronic urticaria is superior to using histamine H1 receptor antagonist alone. The commonly used non antihistamine drugs include leukotriene receptor antagonist, glucocorticoid, tricyclic antidepressants, immunosuppressants, biologics, etc. But the non-antihistamine drugs have more side effects. It is recommended to weigh the pros and cons before using these drugs, and we should also pay attention to monitoring the occurrence of the side effects during using.


comments powered by Disqus

全文

引用

引用本文: 秋秋 张, 铁池 雷. 慢性荨麻疹非抗组胺药物治疗进展[J]. 临床与病理杂志, 2017, 37(8): 1732-1736.
Cite this article as: ZHANG Qiuqiu, LEI Tiechi . Progress of non-antihistamine therapy of chronic urticaria[J]. Journal of Clinical and Pathological Research, 2017, 37(8): 1732-1736.